Clinical Trial Update: Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

View source ↗

Summary

This clinical trial entry reports a cost-utility analysis plan for ambulatory dose escalation of bispecific antibodies in relapsed multiple myeloma, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple Myeloma in Relapse | Status: RECRUITING